Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 841 / https://doi.org/10.3332/ecancer.2018.841

Case Report

Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen

Fatal interstitial lung disease (ILD) is one of the rare side effects of Panitumumab. Both fatal and non-fatal ILD have been reported mainly in the Japanese population. We report a case of a nonsmoking Caucasian man with the diagnosis of metastatic rectal cancer (K-RAS wild-type) who developed fatal ILD after receiving a Panitumumab-containing chemotherapy regimen. He initially presented with a locally advanced rectal cancer (T3N2M0) for which he received neoadjuvant chemoradiotherapy. Before the rectal surgery, he was found to have liver metastases which were considered potentially resectable. The decision was to delay the rectal surgery and to start systemic treatment. He was started on Modified De Gramont regimen (folinic acid and fluorouracil) plus Oxaliplatin with Panitumumab. Six months later, he underwent rectal surgery which showed a complete response. He continued on systemic treatment while awaiting liver metastasectomy. After three courses of Modified De Gramont plus Oxaliplatin with Panitumumab, he was admitted with few days’ history of increasing shortness of breath. High-resolution computed tomography of the lungs showed the features of interstitial pneumonitis. Despite receiving appropriate treatment, he continued to deteriorate and died due to respiratory failure.

Keywords: colon cancer, unwanted effects/adverse reactions, pharmacology and therapeutics, interstitial lung disease

Loading Article Metrics ... Please wait

Related articles

Case Report: Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment

Abstract | Full Article | PDF | Spanish Published: 14 May 2019 / https://doi.org/10.3332/ecancer.2019.930

Clinical Study: Relevance of minor discrepancies at second pathology review in gynaecological cancer

Abstract | Full Article | PDF Published: 13 May 2019 / https://doi.org/10.3332/ecancer.2019.929

Research: Associated factors with the knowledge of nurses of a high complexity oncology centre in Brazil, on the management of cancer pain

Abstract | Full Article | PDF Published: 09 May 2019 / https://doi.org/10.3332/ecancer.2019.928

Short Communication: Prepectoral implant-based breast reconstruction: a joint consensus guide from UK, European and USA breast and plastic reconstructive surgeons

Abstract | Full Article | PDF Published: 07 May 2019 / https://doi.org/10.3332/ecancer.2019.927

Conference Report: Highlights from the 11th Breast-Gynecological and Immunooncology International Cancer Conference (BGICC), 17–18 January 2019, Egypt

Abstract | Full Article | PDF Published: 01 May 2019 / https://doi.org/10.3332/ecancer.2019.926



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation